OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership
28 Februar 2024 - 7:45AM
Business Wire
On February 28, 2024, at 6:00 p.m. CET /
12:00 a.m. ET.
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE), will host a live webcast on February 28, 2024, at 6:00
p.m. CET to discuss the global collaboration and license agreement
with AbbVie and outline the Company’s strategic focus moving
forward.
The live webcast will be available at the following link:
WEBCAST
Link:
https://channel.royalcast.com/landingpage/oseimmunotherapeutics-en/20240228_1/
A replay of the webcast following the event will be available on
the Company’s website: https://ose-immuno.com/en/
ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is a
biotech company dedicated to developing first-in-class assets in
immuno-oncology (IO) and immuno-inflammation (I&I). The
Company’s current well-balanced first-in-class clinical pipeline
includes:
- Tedopi® (immunotherapy activating tumor specific
T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is
the Company’s most advanced product; positive results from the
Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients
in secondary resistance after checkpoint inhibitor failure. Other
Phase 2 trials, sponsored by clinical oncology groups, of Tedopi®
in combination are ongoing in solid tumors.
- OSE-279 (anti-PD1): first positive results in the
ongoing Phase 1/2 in solid tumors.
- OSE-127 - lusvertikimab (humanized monoclonal antibody
antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis
(sponsor OSE Immunotherapeutics); ongoing preclinical research in
leukemia (OSE Immunotherapeutics).
- FR-104/VEL-101 (anti-CD28 monoclonal antibody):
developed in partnership with Veloxis Pharmaceuticals, Inc. in
transplantation; ongoing Phase 1/2 in renal transplant (sponsor
Nantes University Hospital); Phase 1 ongoing in the US (sponsor
Veloxis Pharmaceuticals, Inc.).
- BI 765063 and BI 770371 (anti-SIRPα monoclonal
antibodies on CD47/SIRPα pathway) developed in partnership with
Boehringer Ingelheim in advanced solid tumors; positive Phase 1
dose escalation results in monotherapy and in combination, in
particular with anti-PD-1 antibody ezabenlimab; international Phase
1b ongoing clinical trial in combination with ezabenlimab alone or
with other drugs in patients with recurrent/metastatic head and
neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma
(HCC).
- OSE-230 (ChemR23 agonist mAb) developed in partnership
with AbbVie in chronic inflammation.
OSE Immunotherapeutics expects to generate further significant
value from its three proprietary drug discovery platforms, which
are central to its ambitious goal to deliver next-generation
first-in-class immunotherapies:
- Pro-resolutive mAb platform focused on targeting and
advancing inflammation resolution and optimizing the therapeutic
potential of targeting Neutrophils and Macrophages in I&I.
OSE-230 (licensed to AbbVie) is the first candidate
generated by the platform, additional discovery programs ongoing on
new pro-resolutive GPCRs.
- Myeloid Checkpoint platform focused on optimizing the
therapeutic potential of myeloid cells in IO by targeting immune
regulatory receptors expressed by Macrophages and Dendritic cells.
BI 765063 and BI 770371 (licensed to Boehringer
Ingelheim) are the most advanced candidate generated by the
platform. Ongoing additional discovery programs, in particular with
positive preclinical results obtained in monotherapy with new
anti-CLEC-1 mAbs.
- Cytokine platform focused on leveraging the Cis-Delivery
of cytokine in IO and I&I. BiCKI® is a bispecific fusion
protein platform built on the key backbone component of anti-PD1
combined with a new immunotherapy target to increase anti-tumor
efficacy. BiCKI®-IL-7v is the most advanced BiCKI® candidate
targeting anti-PD1xIL-7. Ongoing additional discovery programs on
Cis-Demasking technologies.
Additional information about OSE Immunotherapeutics assets is
available on the Company’s website: www.ose-immuno.com Click and
follow us on Twitter and LinkedIn
Forward-looking statements This press release contains
express or implied information and statements that might be deemed
forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are
based upon certain assumptions and assessments made by OSE
Immunotherapeutics’ management in light of its experience and its
perception of historical trends, current economic and industry
conditions, expected future developments and other factors they
believe to be appropriate. These forward-looking statements include
statements typically using conditional and containing verbs such as
“expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”,
their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on May 2, 2023, including the annual financial report
for the fiscal year 2022, available on the OSE Immunotherapeutics’
website. Other than as required by applicable law, OSE
Immunotherapeutics issues this press release at the date hereof and
does not undertake any obligation to update or revise the
forward-looking information or statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227277635/en/
Sylvie Détry sylvie.detry@ose-immuno.com
Nicolas Poirier Chief Executive Officer
nicolas.poirier@ose-immuno.com
French Media: FP2COM Florence Portejoie
fportejoie@fp2com.fr +33 6 07 768 283
U.S. Media Contact RooneyPartners LLC Kate Barrette
kbarrette@rooneypartners.com +1 212 223 0561
OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
OSE Immunotherapeutics (EU:OSE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024